Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Recce Pharmaceuticals Ltd (RCE.AX)
AUD0.37
-0.02 (-5.19%)
AU ASX Healthcare Biotechnology
Address
Aurora Place 2000
Sydney, NSW, AU
Sydney, NSW, AU
CEO
James Hamilton-Bray Graham
Website
recce.com.au
IPO
2016-01-14
ISIN AU000000RCE5
Also trades on
Australian Securities Exchange · RCE.AX (AUD)
Other OTC · RECEF (USD)
Description
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.37
-0.02 (-5.19%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
137.8K
Beta
0.39
Float Shares
124.84M
Free Float %
43.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.79% | +15.79% | +14.58% | +1.85% | +12.24% | -15.38% | +59.42% | -2.55% | -47.12% | +79.19% | +85.16% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.37
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-145.72
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+49.3% ★ Q4'25: -100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+9.3% Q4'25: -37.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-207.6%
-
EBIT margin Biotechnology: +0.0%-271.8%
-
ROIC Biotechnology: -16.1%— Q4'25: +690.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+33.8% Q4'25: +61.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.53× Q4'25: -0.21× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 2 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
1.64M
est: 1.12M (+46.0%)
|
3.08M
est: 1.50M (+105.7%)
|
4.37M
est: 3.11M (+40.4%)
|
5.03M
est: 2.89M (+74.3%)
|
7.51M
est: 5.23M (+43.7%)
|
4.68M
3.65M – 5.70M
-10.5% YoY
|
5.26M
5.11M – 5.42M
+12.5% YoY
|
6.40M
5.65M – 7.15M
+21.6% YoY
|
| EBITDA |
-14.77M
est: -1.12M (-1,216.9%)
|
-13.87M
est: -1.50M (-824.8%)
|
-16.99M
est: -3.11M (-446.3%)
|
-21.35M
est: -2.89M (-640.0%)
|
-20.33M
est: -5.23M (-289.1%)
|
-4.68M
-5.70M – -3.65M
+10.5% YoY
|
-5.26M
-5.42M – -5.11M
-12.5% YoY
|
-6.40M
-7.15M – -5.65M
-21.6% YoY
|
| EBIT |
-15.07M
est: -1.12M (-1,243.2%)
|
-14.06M
est: -1.50M (-837.3%)
|
-17.21M
est: -3.11M (-453.3%)
|
-21.72M
est: -2.89M (-652.8%)
|
-20.41M
est: -5.23M (-290.5%)
|
-4.68M
-5.70M – -3.65M
+10.5% YoY
|
-5.26M
-5.42M – -5.11M
-12.5% YoY
|
-6.40M
-7.15M – -5.65M
-21.6% YoY
|
| Net Income |
-13.51M
est: -7.88M (-71.5%)
|
-10.99M
est: -8.06M (-36.2%)
|
-13.08M
est: -14.52M (+10.0%)
|
-17.66M
est: -17.66M (+0.0%)
|
-21.43M
est: -17.70M (-21.1%)
|
-15.64M
-16.59M – -14.69M
+11.6% YoY
|
-11.60M
-42.66M – -8.77M
+25.8% YoY
|
-6.16M
-7.10M – -5.22M
+46.9% YoY
|
| SGA |
7.51M
est: 2.19M (+242.4%)
|
3.37M
est: 2.93M (+14.8%)
|
6.08M
est: 6.08M (0.0%)
|
7.11M
est: 5.64M (+26.1%)
|
9.70M
est: 10.22M (-5.1%)
|
9.14M
7.15M – 11.14M
-10.5% YoY
|
10.29M
9.98M – 10.59M
+12.5% YoY
|
12.51M
11.05M – 13.98M
+21.6% YoY
|
| EPS |
-0.09
est: -0.03 (-159.0%)
|
-0.06
est: -0.03 (-83.7%)
|
-0.07
est: -0.06 (-21.4%)
|
-0.10
est: -0.08 (-25.8%)
|
-0.09
est: -0.10 (+9.6%)
|
-0.07
-0.07 – -0.06
+34.0% YoY
|
-0.11
-0.18 – -0.04
-64.4% YoY
|
-0.03
-0.03 – -0.02
+76.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-38.10M
OE per share TTM
-0.16
Owner's Yield
-23.96%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
20.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-25.5K
Shares Outstanding
289.18M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James Hamilton-Bray Graham GAICD | Chief Executive Officer, MD & Executive Director | 1M | male |
| Arthur Kollaras | Principal Engineer & Head of Manufacturing | 717.9K | male |
| John K. A. Prendergast | Executive Chairman of the Board | 387.2K | — |
| Michele Keryn Diliza | Chief Scientific Director & Executive Director | 379.8K | female |
| Justin Ward | Principal Quality Chemist & Executive Director | 319.6K | — |
| Alan W. Dunton | Chief Medical Advisor & Independent Non Executive Director | 75.0K | — |
| Daniel Astudillo | Head of Marketing | — | male |
| Justin Reynolds | Chief Financial Officer | — | male |
| Maggie Niewidok | Company Secretary | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RCE.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
